PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
about
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerNOD1 deficiency impairs CD44a/Lck as well as PI3K/Akt pathway.Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway.Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics.A liaison between mTOR signaling, ribosome biogenesis and cancerPrognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.miR-199a-5p regulates β1 integrin through Ets-1 to suppress invasion in breast cancer.Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells.S-Adenosylmethionine-mediated apoptosis is potentiated by autophagy inhibition induced by chloroquine in human breast cancer cells.The effect of IL-1β on synaptophysin expression and electrophysiology of hippocampal neurons through the PI3K/Akt/mTOR signaling pathway in a rat model of mesial temporal lobe epilepsy.MicroRNA-H4-5p encoded by HSV-1 latency-associated transcript promotes cell proliferation, invasion and cell cycle progression via p16-mediated PI3K-Akt signaling pathway in SHSY5Y cells.Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression
P2860
Q26753162-FA26741A-EF3F-4235-B98B-B5D286F12382Q33774237-898E5C4B-76AA-44D2-947F-BE89CD761D66Q35147446-281F61A7-2CFA-4B20-997E-3337543754BCQ36593659-D617C944-24FD-4B1D-8C2E-4F9313F6DF1FQ36615429-A3B9D8C5-78E0-474D-A9FB-20D3265A4532Q36653584-C5772BAA-2418-4FA1-A6F3-511EA25CC6BBQ37098277-5B3F6C76-82F1-44AA-9834-8D5234C59D63Q37417255-C1503D17-7FB8-4081-8057-DCAFF6D8A2B0Q38703082-E44D56CC-2431-4713-8DC2-CE23EA36D72BQ40458487-0A0D7206-5A29-4436-8EF1-5DF0379C1A32Q41084666-51EC8B68-B5A2-47AD-8EC1-5AEE542D8F02Q44174238-0EE91206-1223-4962-9517-C8AA21C3C4E2Q57056183-5A005308-113A-4CC0-A95F-EBBD800DE60F
P2860
PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
PI3K/AKT/mTOR pathway inhibito ...... s for breast cancer therapies?
@en
type
label
PI3K/AKT/mTOR pathway inhibito ...... s for breast cancer therapies?
@en
prefLabel
PI3K/AKT/mTOR pathway inhibito ...... s for breast cancer therapies?
@en
P2860
P1476
PI3K/AKT/mTOR pathway inhibito ...... s for breast cancer therapies?
@en
P2093
Jame Abraham
P2860
P356
10.1586/14737140.2015.961429
P577
2014-10-11T00:00:00Z